Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Account Payables: 2016-2024

Historic Change in Account Payables for Dianthus Therapeutics (DNTH) over the last 9 years, with Dec 2024 value amounting to $8.2 million.

  • Dianthus Therapeutics' Change in Account Payables fell 46.84% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 8.53%. This contributed to the annual value of $8.2 million for FY2024, which is 1139.18% up from last year.
  • As of FY2024, Dianthus Therapeutics' Change in Account Payables stood at $8.2 million, which was up 1,139.18% from $661,000 recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Change in Account Payables registered a high of $8.2 million during FY2024, and its lowest value of -$801,000 during FY2022.
  • Over the past 3 years, Dianthus Therapeutics' median Change in Account Payables value was $661,000 (recorded in 2023), while the average stood at $2.7 million.
  • In the last 5 years, Dianthus Therapeutics' Change in Account Payables tumbled by 175.95% in 2021 and then skyrocketed by 1,139.18% in 2024.
  • Dianthus Therapeutics' Change in Account Payables (Yearly) stood at $948,000 in 2020, then slumped by 175.95% to -$720,000 in 2021, then declined by 11.25% to -$801,000 in 2022, then surged by 182.52% to $661,000 in 2023, then spiked by 1,139.18% to $8.2 million in 2024.